stachyose

Stachyose is a nondigestible carbohydrate classified as an oligosaccharide composed of two galactose units, one glucose unit, and one fructose unit linked sequentially. Chemically, it belongs to the raffinose family of oligosaccharides (RFOs), sharing structural similarities with raffinose and verbascose. Unlike simple sugars such as glucose or sucrose, humans lack the endogenous enzymes necessary to effectively digest the α‑1,6 glycosidic bonds present in stachyose, which leads to its passage through the small intestine intact and into the colon. In plants, especially legumes like soybeans, peas, and various beans, stachyose serves as a transport sugar and plays roles in carbon allocation and stress responses. Because of its unique molecular structure, stachyose contributes to the dietary fiber content of foods, conferring both nutritional and functional properties. This oligosaccharide’s nondigestibility classifies it alongside other fermentable fibers that reach the large intestine where resident microbiota metabolize it. During fermentation, gut bacteria such as Bifidobacteria and Lactobacilli utilize stachyose as a substrate, generating short‑chain fatty acids (SCFAs) like acetate and butyrate, which are key to colonic health and systemic metabolic effects. For humans consuming plant‑rich diets, especially those emphasizing legumes, stachyose intake can be significant and contribute to gut microbial composition and activity. Stachyose is also used in food science for its low sweetness (approximately 28% that of sucrose) and functional properties such as water solubility and stability. These qualities make it useful as a bulk carbohydrate or functional ingredient in formulated foods. Despite increasing interest in its health effects and applications in functional foods, stachyose does not have defined dietary reference intakes, because it is not an essential nutrient. Research continues to explore its prebiotic mechanisms and potential benefits in human health contexts.

The primary recognized function of stachyose in human nutrition is its role as a prebiotic. Once ingested, stachyose resists digestion in the upper gastrointestinal tract because humans lack α‑galactosidase enzymes capable of hydrolyzing its galactosidic linkages. This characteristic allows stachyose to reach the colon largely intact, where it becomes a fermentable substrate for saccharolytic gut microbiota. Beneficial bacterial genera such as Bifidobacterium, Lactobacillus, Faecalibacterium, and others selectively metabolize stachyose through enzymatic activities, leading to significant fermentation processes. These microbial fermentations produce short‑chain fatty acids (SCFAs) such as acetate and butyrate, which serve as energy sources for colonocytes, help maintain mucosal integrity, and have systemic anti‑inflammatory effects. Multiple in vitro and animal studies have documented that stachyose fermentation increases SCFA levels and promotes beneficial shifts in microbial ecology, including enhanced beta diversity and relative abundances of beneficial bacteria, while reducing potentially pathogenic genera. These changes are associated with improved gut barrier function, modulation of immune responses, and reduced epithelial inflammation in experimental models. Clinical and preclinical research also indicates potential metabolic benefits of stachyose. For example, oral administration of stachyose in high‑fat diet animal models resulted in improvements in metabolic syndrome features including reduced hepatic steatosis, improved lipid profiles, and decreased systemic inflammation. These outcomes were attributed in part to enhanced gut microbiota composition and intestinal barrier integrity. Research focusing on colitis models suggests that stachyose supplementation can ameliorate colon tissue damage, decrease pro‑inflammatory cytokines, and restore bacterial homeostasis, pointing to its potential utility in inflammatory gut conditions. Although human clinical trials are limited, emerging data suggest that dietary stachyose could support digestive regularity, mitigate constipation through increased fecal output and motility enhancements, and contribute to mineral absorption by modulating the colonic environment. In addition to gut‑centric benefits, stachyose’s fermentation metabolites may influence systemic metabolic pathways, including bile acid modulation and improved lipid metabolism. While these functions highlight stachyose’s promise as a functional food component, it is important to note that individual responses vary, and gastrointestinal symptoms such as gas and bloating can occur due to increased fermentation, especially when intake is rapidly increased.

Unlike essential nutrients such as vitamins and minerals, stachyose does not have established recommended dietary allowances (RDAs), adequate intakes (AIs), or tolerable upper intake levels as defined by NIH Office of Dietary Supplements or other authoritative bodies. This is because stachyose is a non‑essential carbohydrate without a recognized deficiency disease and its primary health roles relate to prebiotic and fermentative effects rather than meeting a physiological requirement. Dietary intake of stachyose varies widely depending on consumption patterns of legumes, vegetables, and other plant‑based foods rich in fermentable oligosaccharides. Typical Western diets with moderate legume intake may provide a few grams of stachyose per day, whereas diets rich in beans, peas, and related foods may contribute higher amounts. Research recommendations for fermentable fiber intake often suggest a total dietary fiber intake of 25–38 grams per day for adults, but this includes a broad category of fibers including non‑stachyose carbohydrates. No authoritative body has specified how much stachyose alone is optimal, but observational and interventional studies exploring prebiotic effects have used stachyose doses ranging from a few grams to higher amounts in supplemental form to detect shifts in microbiota and metabolic markers. Individual tolerance also influences recommended intake: rapid increases in fermentable carbohydrates such as stachyose can induce gastrointestinal discomfort in some individuals due to increased gas production. For practical purposes, incorporating a variety of stachyose‑containing foods such as legumes, peas, and certain vegetables into a balanced diet can contribute to beneficial gut microbial fermentation without needing specific numeric targets. Individuals with sensitive digestion may benefit from gradual increases in intake and from culinary practices like soaking and thorough cooking to reduce initial oligosaccharide loads and minimize bloating.

Stachyose is not an essential nutrient, and therefore there is no clinically recognized deficiency syndrome attributable to its absence from the diet. Unlike vitamins such as vitamin C, whose deficiency leads to scurvy, or minerals such as iodine whose absence causes goiter, the absence of stachyose does not produce a specific disease state. However, stachyose contributes to the fermentable carbohydrate pool in the diet, and diets extremely low in fermentable fibers may be associated with suboptimal gut microbial diversity and reduced production of beneficial short‑chain fatty acids. While not classified as a deficiency, reduced production of SCFAs such as butyrate in the colon has been associated with a range of adverse health outcomes including compromised gut barrier function, low‑grade inflammation, and alterations in metabolic health. Populations with low dietary fiber intakes often exhibit less diverse gut microbiota and lower SCFA output, which may correlate with increased risk of metabolic and inflammatory conditions, although causality is complex and multifactorial. Symptoms that may theoretically be linked to low fermentable carbohydrate intake, rather than stachyose per se, include irregular bowel habits, reduced stool bulk, and less frequent fermentation‑driven SCFA production. However, these symptoms are general manifestations of low overall fiber intake rather than specific to stachyose absence. Populations at risk for low fermentable carbohydrate intake include those consuming highly processed, low‑fiber diets, individuals with restrictive eating patterns, or those following elimination diets without adequate plant‑based foods. In such cases, dietary patterns supporting a range of fermentable fibers, including stachyose, can contribute to a healthier gut microbiome profile.

Stachyose is predominantly found in plant foods, especially in the seeds of legumes and certain vegetables. Since comprehensive USDA data on stachyose content are limited, data from food composition research indicate that legumes such as beans, peas, and soybeans are among the richest dietary sources. For example, Chinese foxglove seeds and various beans exhibit particularly high levels according to food nutrient profiling, followed by soybeans, green gram, mung beans, asparagus beans, peas, yardlong beans, black gram, and others. These foods deliver milligram‑level quantities of stachyose per 100 grams of raw or prepared weight. Other plant sources such as fenugreek, alfalfa, and clovers also contain measurable amounts, reflecting the widespread occurrence of raffinose family oligosaccharides in legume seeds. Vegetables such as broccoli, cabbage, and onions contain smaller stachyose amounts as part of their total oligosaccharide profiles. Preparation methods can influence stachyose content: soaking and thorough boiling of legumes can reduce oligosaccharide levels by leaching them into the cooking water or partially hydrolyzing them. This can improve digestibility and reduce gastrointestinal symptoms for sensitive individuals. For those seeking to maximize stachyose intake for prebiotic effects, including a variety of legumes and beans in meals—such as soups, stews, salads, and side dishes—can provide both fermentable carbohydrates and complementary nutrients like protein, vitamins, and minerals.

Stachyose is not absorbed in the small intestine because humans lack the α‑galactosidase enzyme necessary to break its α‑1,6 glycosidic bonds. This biochemical property distinguishes it from digestible sugars such as glucose and sucrose. As a result, stachyose passes into the large intestine where colonic microbes ferment it. The fermentation process releases short‑chain fatty acids (SCFAs) like acetate and butyrate, which are absorbed by colonocytes and have systemic effects including energy provision to colonic cells and modulation of immune responses. The bioavailability concept for stachyose therefore pertains to its microbial utilization rather than intestinal absorption; its effects depend on the composition and functional capacity of an individual’s gut microbiota. Factors enhancing fermentation include a diverse, balanced microbiome with abundant saccharolytic bacteria such as Bifidobacterium and Lactobacillus species. Conversely, a dysbiotic microbiota with reduced fermentative capacity may yield less SCFA production. Gut pH, transit time, and overall dietary patterns also influence how stachyose is metabolized in the colon. High‑fat or low‑fiber diets can alter microbial ecology and reduce fermentative efficiency, whereas diets rich in a variety of fermentable fibers provide substrates that support robust microbial activity. Because stachyose does not enter systemic circulation intact, its bioavailability is measured in terms of its contribution to microbial fermentation and ensuing health outcomes rather than traditional nutrient absorption metrics.

Supplements containing stachyose are marketed for gut health, leveraging its prebiotic fermentation to support beneficial bacterial populations and SCFA production. For many individuals, consuming stachyose‑rich foods provides adequate fermentable substrate without the need for supplementation. Supplements may be considered for those seeking targeted increases in prebiotic intake, particularly individuals with suboptimal diets low in legumes and fermentable fibers. However, gastrointestinal tolerance should be evaluated; rapid introduction of high doses of fermentable carbohydrates can lead to gas, bloating, and discomfort due to increased microbial fermentation. Starting with lower doses and gradually increasing intake can help mitigate symptoms. Quality considerations are important when selecting stachyose supplements. Products should specify the source, purity, and non‑GMO status if desired, and reputable third‑party testing ensures the absence of contaminants. Because stachyose is a carbohydrate and not an essential nutrient, supplements should complement—not replace—a balanced diet rich in plant‑based foods. Individuals with specific digestive disorders such as irritable bowel syndrome (IBS) should consult healthcare professionals, as fermentable oligosaccharides can exacerbate symptoms in some contexts. Pregnant or lactating women and people with complex medical conditions should also seek individualized guidance before initiating supplementation.

No tolerable upper intake level (UL) has been defined for stachyose, as it is a non‑essential carbohydrate with minimal systemic absorption. Toxicity in the classical sense does not occur; however, excessive intake of fermentable oligosaccharides can cause gastrointestinal side effects due to extensive fermentation. Common symptoms when consuming high amounts include gas, bloating, flatulence, and abdominal discomfort. These outcomes relate to the production of gases such as hydrogen, carbon dioxide, and methane during microbial metabolism rather than toxicity. Individuals sensitive to fermentable fibers should introduce stachyose gradually and pair legumes with cooking methods that reduce oligosaccharide content. For people with small intestinal bacterial overgrowth (SIBO), IBS, or other conditions involving dysregulated gut fermentation, high stachyose intake may exacerbate symptoms. In such cases, individualized dietary planning that balances fermentable carbohydrate intake with tolerance can help manage symptoms while still supporting gut health. Because stachyose is metabolized by gut bacteria and not absorbed, systemic toxic effects have not been documented in humans at dietary or supplemental levels.

Stachyose itself does not directly interact with medications via systemic pharmacokinetic mechanisms because it is not absorbed in significant amounts into the bloodstream. However, its modulation of gut microbiota may indirectly influence the metabolism of certain drugs that undergo microbial biotransformation. For example, gut microbial composition can impact the processing of drugs such as digoxin, certain chemotherapeutics, and other compounds that rely on microbial enzymes for activation or inactivation. While direct clinical evidence of stachyose altering drug efficacy is limited, conceptual interactions through microbiome shifts warrant attention, especially for medications with narrow therapeutic indices. Patients taking antibiotics may experience altered gut microbiota composition, which could influence how fermentable carbohydrates like stachyose are metabolized. Antibiotic‑induced dysbiosis can temporarily reduce the populations of bacteria that ferment stachyose, potentially diminishing its prebiotic effects. Conversely, changes in microbiota from stachyose intake might influence drug metabolism over time, although clinical data are lacking. Individuals on complex medication regimens should discuss dietary changes with healthcare providers, particularly if gastrointestinal conditions or altered microbial states are present.

Common Forms: powder, functional food additive

Typical Doses: Varies; often 3–8 g/day in prebiotic studies

When to Take: With meals or spread across day to improve tolerance

Best Form: Not applicable (acts locally in colon)